Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab and Tremelimumab with Chemotherapy in Advanced Solid Tumors
NCT02658214Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2016
- Primary completion
- Nov 2019
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 2
01
Overview
Phase 1, open-label trial of durvalumab and tremelimumab in ovarian cancer, head and neck squamous cell carcinoma (HNSCC), triple negative breast cancer (TNBC) and 4 more (7 arms), sponsored by AstraZeneca. Primary endpoints: Laboratory findings and Incidence of Adverse Events at 3 years and Tumor assessment based on RECIST 1.1 at 3 years. Started Apr 2016; status: completed.
02
Drugs
durvalumabtremelimumab
03
Conditions
ovarian cancerhead and neck squamous cell carcinoma (HNSCC)triple negative breast cancer (TNBC)small cell lung cancer (SCLC)gastric cancer (GC)
Beyond the preview
Go deeper on NCT02658214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02658214.